Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Free Report) has been assigned an average rating of “Hold” from the nine research firms that are presently covering the stock, Marketbeat.com reports. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $10.00.
ZNTL has been the subject of several research reports. Guggenheim lowered their price objective on shares of Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, November 15th. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of Zentalis Pharmaceuticals in a research report on Friday, November 15th.
Get Our Latest Analysis on ZNTL
Institutional Inflows and Outflows
Zentalis Pharmaceuticals Price Performance
Zentalis Pharmaceuticals stock opened at $2.26 on Friday. The stock has a market cap of $161.06 million, a price-to-earnings ratio of -0.91 and a beta of 1.86. Zentalis Pharmaceuticals has a 1 year low of $2.16 and a 1 year high of $18.07. The firm has a 50-day moving average of $3.11 and a two-hundred day moving average of $3.36.
Zentalis Pharmaceuticals (NASDAQ:ZNTL – Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.36. Research analysts expect that Zentalis Pharmaceuticals will post -2.48 earnings per share for the current year.
Zentalis Pharmaceuticals Company Profile
Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.
Further Reading
- Five stocks we like better than Zentalis Pharmaceuticals
- What is a Dividend King?
- Oracle Announces Game-Changing News for the AI Industry
- About the Markup Calculator
- Netflix Adds 19 Million Subscribers, Growth Is Far From Over
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Tempus AI: A Game-Changer in AI-Powered Healthcare
Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.